Pieris Pharmaceuticals Stock (NASDAQ:PIRS)


RevenueOwnershipFinancialsChart

Previous Close

$15.47

52W Range

$6.20 - $22.32

50D Avg

$16.61

200D Avg

$13.78

Market Cap

$21.14M

Avg Vol (3M)

$20.96K

Beta

0.66

Div Yield

-

PIRS Company Profile


Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis; and immune-oncology program comprises Cinrebafusp alfa, a 4-1BB/ HER2 bispecific for the treatment of HER2-high and HER2-low expressing gastric cancers. The company also develops PRS-344/S095012, a bispecific anticalin-antibody fusion protein targeting 4- 1BB and PD-L1 for immuno-oncology diseases that is in phase 1 clinical trial; and PRS-352, a preclinical-stage program addressing undisclosed targets for immuno-oncology diseases. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a clinical trial collaboration and supply agreement with Eli Lilly and Company. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

46

IPO Date

Jan 02, 2015

Website

PIRS Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceSep 20Jun 20Mar 20
Customer Revenue$2.58M$10.93M$8.88M
Collaboration Revenue$361.00K$316.00K$4.38M

Fiscal year ends in Dec 23 | Currency in USD

PIRS Financial Summary


Dec 23Dec 22Dec 21
Revenue$42.81M$25.90M$31.42M
Operating Income$-29.76M$-43.47M$-51.83M
Net Income$-24.54M$-31.25M$-43.37M
EBITDA$-29.76M$-35.30M$-48.15M
Basic EPS$-0.27$-0.42$-0.67
Diluted EPS$-0.27$-0.42$-0.67

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q1 23May 10, 23 | 11:03 AM
Q4 22Mar 29, 23 | 3:40 PM
Q3 22Nov 02, 22 | 12:23 PM

Peer Comparison


TickerCompany
CKPTCheckpoint Therapeutics, Inc.
CUECue Biopharma, Inc.
XFORX4 Pharmaceuticals, Inc.
ACHLAchilles Therapeutics plc
MREOMereo BioPharma Group plc
ADCTADC Therapeutics SA
PDSBPDS Biotechnology Corporation
ADAPAdaptimmune Therapeutics plc
CRVSCorvus Pharmaceuticals, Inc.
MDNAMedicenna Therapeutics Corp.
TERNTerns Pharmaceuticals, Inc.
INZYInozyme Pharma, Inc.
AGENAgenus Inc.
AFMDAffimed N.V.
LPTXLeap Therapeutics, Inc.